On December 3, 2019 the National Health Surveillance Agency (ANVISA) approved the Collegiate Board of Officers Resolution which regulates the manufacture, prescription, import and commercialization of products containing Cannabis sativa and sets forth the rules for monitoring and surveillance of products containing referred active ingredient for medicinal purposes.
Products containing cannabis will only be allowed for sale upon presentation of a special medical prescription which must be retained by the pharmacy or drugstore.
The regulation will be reviewed within 3 years.
The approved regulation will be published in the Official Gazette within the next days and will become in force after a 90-day vacatio legis period.
Veirano's Life Sciences & Healthcare team is at your attention to provide further information on this matter.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.